(146 days)
No
The description focuses on the mechanical design and materials of the hip replacement system, with no mention of AI or ML capabilities.
Yes
The device is a hip replacement system, indicated for the reconstruction of a severely disabled and/or very painful hip joint due to various medical conditions, clearly fitting the definition of a therapeutic device.
No
Explanation: The document describes a hip replacement system, which is a medical implant used for treatment, not for diagnosing a condition. Its function is to replace a damaged hip joint, not to identify a disease or medical condition.
No
The device description clearly describes a physical hip replacement stem and associated instruments, which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a surgical implant for replacing the femoral portion of a hip joint. This is a therapeutic device, not a diagnostic one.
- Device Description: The description details a physical prosthesis (stem, neck component) and surgical instruments for implantation. This aligns with a surgical device, not a device used to test samples from the body.
- No mention of in vitro testing: There is no indication that this device is used to examine specimens (like blood, urine, or tissue) outside of the body to provide diagnostic information.
IVD devices are used to perform tests on samples taken from the human body to provide information for diagnosis, monitoring, or screening. This device is a physical implant used in surgery.
N/A
Intended Use / Indications for Use
The MARGRON™ Hip Replacement System is intended for primary or revision restruction, without bone cement, of the femoral portion of a severely disabled and/or very painful hip joint, where radiographic evidence of sufficient sound bone is present.
The patient should be skeletally mature. The patient's condition should be due to one or more of the following:
- Osteoarthritis
- Rheumatoid arthritis
- Tumor conditions involving the upper third of the femur or the acetablym
- Ankylosing spondylitis
- Psoriatic arthritis
- Old osteomyelitis - with a long infection-free period and a normal WBC. ESR and C-reactive protein
- Non union of femoral neck fracture or avascular necrosis of the femoral head
- Post-traumatic fracture/dislocation of the hip
- Revision of an unsuccessful arthrodesis with either poor positioning or pain in the hip, or where low back pain or knee pain is becoming disabling
- Revision of an unsuccessful cemented or un-cemented hip replacement stem, providing sufficient bone stock is present
- Revision of a previous unsuccessful femoral osteotomy, Girdlestone resection, cup arthroplasty or hemi arthroplasty.
Product codes
87 MEH, LPH
Device Description
The MARGRON 100 hip replacement stem has been designed to be used in an uncemented mode in bone which is of good quality physiologically and which will heal quickly.
The MARGRON TM Femoral Stem is a modular prosthesis consisting of
- A tapering stem cone with two different speed external threads and longitudinal . derotation columns.
- A neck component which allows the optimum angle of anteversion to be selected ● after stem insertion.
- . Precision milling and tapping is used to prepare the femur and stem insertion is by "screw home" rotation.
- . A unique set of instruments have been designed to insert and extract the prosthesis.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
femoral portion of a severely disabled and/or very painful hip joint, upper third of the femur or the acetablym
Indicated Patient Age Range
The patient should be skeletally mature.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
All materials used in the fabrication of this MARGRON™ Hip Replacement System were evaluated with the original design through physical testing (fatigue, torque and corrosion testing) and biocompatibility testing. It has been shown to be substantially equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
MARGRON™ Hip Replacement System (K992158)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3353 Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis.
(a)
Identification. A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.(b)
Classification. Class II.
0
032641
Summary of Safety and Effectiveness 10.
| Manufacturer: | Portland Orthopaedics Pty. Ltd.
Unit 3, 44 McCauley Street
Matraville, NSW, 2036
Australia |
|------------------------|-----------------------------------------------------------------------------------------------------|
| Contact: | David Sekel
CEO, Portland Orthopaedics |
| Telephone Number: | 011 (61) 2 9666 8444 |
| Fax Number: | 011 (61) 2 9666 8544 |
| Date Summary Prepared: | August 15, 2003 |
| Product Trade Name: | MARGRON™ Hip Replacement System |
| Common Name: | Modular Femoral Hip Replacement System |
| Classification Name: | Hip joint/ceramic/polymer semi-constrained
Cemented or nonporous uncemented prosthesis |
| Product Codes: | 87 MEH & LPH - Device, Fixation, Proximal
Femoral, Implant |
| Predicate Device: | MARGRON™ Hip Replacement System
(K992158) |
Page 1 of 3
MARGRON™ Hip Replacement System Special 510(k) Notification
.
:
1
KO32641
Device Description:
The MARGRON 100 hip replacement stem has been designed to be used in an uncemented mode in bone which is of good quality physiologically and which will heal quickly.
The MARGRON TM Femoral Stem is a modular prosthesis consisting of
- A tapering stem cone with two different speed external threads and longitudinal . derotation columns.
- A neck component which allows the optimum angle of anteversion to be selected ● after stem insertion.
- . Precision milling and tapping is used to prepare the femur and stem insertion is by "screw home" rotation.
- . A unique set of instruments have been designed to insert and extract the prosthesis.
Intended Use/Indications:
The MARGRONTM Hip Replacement System is intended for primary or revision restruction, without bone cement, of the femoral portion of a severely disabled and/or very painful hip joint, where radiographic evidence of sufficient sound bone is present.
The patient should be skeletally mature. The patient's condition should be due to one or more of the following:
- Osteoarthritis ●
- . Rheumatoid arthritis
- . Tumor conditions involving the upper third of the femur or the acetablym
- Ankylosing spondylitis .
- Psoriatic arthritis .
- � Old osteomyelitis - with a long infection-free period and a normal WBC. ESR and C-reactive protein
- . Non union of femoral neck fracture or avascular necrosis of the femoral head
- . Post-traumatic fracture/dislocation of the hip
- . Revision of an unsuccessful arthrodesis with either poor positioning or pain in the hip, or where low back pain or knee pain is becoming disabling
- Revision of an unsuccessful cemented or un-cemented hip replacement stem, . providing sufficient bone stock is present
- Revision of a previous unsuccessful femoral osteotomy, Girdlestone resection, cup . arthroplasty or hemi arthroplasty.
Page 2 of 3
Portland Orthopaedics Pty. Ltd. MARGRONTM Hip Replacement System Special 510(k) Notification
2
(03244)
Substantial Equivalence:
The MARGRONTM Hip Replacement System is substantially equivalent to the current MARGRONTM Hip Replacement System (K992815) in that:
- the intended use is the same ●
- the same operating principles is used .
- the same final design configuration is incorporated �
- both are labeled as sterile, single patient use .
- both are packaged and labeled using the same materials and processes �
Summary of Testing:
All materials used in the fabrication of this MARGRON™ Hip Replacement System were evaluated with the original design through physical testing (fatigue, torque and corrosion testing) and biocompatibility testing. It has been shown to be substantially equivalent to the predicate device.
Page 3 of 3
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, rendered in black.
Public Health Service
JAN 2 0 2004
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. David Sekel CEO Portland Orthopaedics Pty. Ltd Unit 3, 44 McCauley Strect Matraville, NSW, 2036 Australia
Re: K032641 : Ito22011 Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: II Product Code: MEH, LPH Dated: December 18, 2003 Received: December 22, 2003
Dear Mr. Sekel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can he found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 - Mr. David Sekel
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), plcasc contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-frec number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours.
Sincerely yours,
Mark N Milliman
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): _
Device Name:
MARGRONTM Hip Replacement System
Indications for Use:
The MARGRON™ Hip Replacement System is intended for primary or revision restruction, without bone cement, of the femoral portion of a severely disabled and/or very painful hip joint, where radiographic evidence of sufficient sound bone is present.
KO32641
The patient should be skeletally mature. The patient's condition should be due to one or more of the following:
- Osteoarthritis .
- Rheumatoid arthritis .
- Tumor conditions involving the upper third of the femur or the acetablum .
- Ankylosing spondylitis ●
- Psoriatic arthritis .
- Old osteomyelitis with a long infection-free period and a normal WBC, ESR and C-reactive protein .
- Non union of femoral neck fracture or avascular necrosis of the femoral head .
- Post-traumatic fracture/dislocation of the hip �
- Revision of an unsuccessful arthrodesis with either poor positioning or pain in the hip, or where . low back pain or knee pain is becoming disabling
- Revision of an unsuccessful cemented or un-cemented hip replacement stem, providing sufficient . bone stock is present
- Revision of a previous unsuccessful femoral ostcotomy, Girdlestone resection, cup arthroplasty or ◆ hemi arthroplasty.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use (Per 21 CFR 801.109) | X OR Over-The-Counter Use |
|---|---|
| --------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------- |
for
| (Division Sign-Off) | |
|---|---|
| Division of General and Restorative Devices | |
| 510(k) Number |
Mark N Millenson
Restorative
Medical Devices
Portland Orthopaedics Pty. Ltd. MARGRONTRA Hip Replacement System Special 510(k) Notification